<unk>  is a SLAMF7-directed immunostimulatory antibody that is FDA approved for the treatment of patients with multiple myeloma (in combination with lenalidomide and dexamethasone) who have received one to three prior therapies..   Common adverse reactions include fatigue, diarrhea, pyrexia, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite, pneumonia (20%).
Elotuzumab
Pertuzumab
Bavituximab
Idarucizumab
Matuzumab
Volociximab
Epratuzumab
Alemtuzumab